The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States
Lynn Malec(Medical College of Wisconsin), Margaret V. Ragni(University of Pittsburgh Medical Center), Julie Jaffray(University of Colorado Anschutz Medical Campus), Char Witmer(Children's Hospital of Philadelphia), Dunlei Cheng(American Thrombosis and Hemostasis Network), Peter A. Kouides(Unity Health System), Robert F. Sidonio(Emory University), Kristina M. Haley(Oregon Health & Science University), Kelsey Johnson(Versiti Blood Center of Wisconsin), Michael Recht(McMaster University), Gilbert White(University of North Carolina at Chapel Hill), Stacy E. Croteau(Boston Children's Hospital)
Cited by 31
Related Papers
Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
PECAM-1 (CD31) Cloning and Relation to Adhesion Molecules of the Immunoglobulin Gene Superfamily
|Science|1990|954
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with Hemophilia
|New England Journal of Medicine|1989|528
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
|American Journal of Hematology|2012|366